Medical Patent News

RSS

Neurotez receives U.S. patent for Leptin to treat Alzheimer's

Neurotez, Inc. today announced the grant of U.S. Patent number 8,227,408 by the United States Patent and Trademark Office covering the company's lead product candidate, Leptin. The patent protects use of the hormone Leptin for treating a progressive cognitive disease, disorder or condition, such as Alzheimer's disease (AD), resulting from accumulation of an amyloid peptide or for improving resilience of cognitive function by modulating the accumulation of the amyloid peptide in brain.

30 Jul 2012

ACT receives Australian patent for human retinal pigment epithelial cells

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has been issued a patent in Australia, patent number 2005325753, "Improved modalities for the treatment of degenerative diseases of the retina."

28 Jul 2012

Illumina sues IBS and Qiagen for infringement of three patents

Illumina, Inc. today announced that the company has sought leave to file counterclaims against Intelligent Bio-Systems, Inc. and Qiagen NV, which recently acquired IBS, in response to the patent lawsuit brought by Columbia University and IBS on March 26, 2012 in U.S. District Court in Wilmington, Delaware.

From Illumina, Inc. 23 Jul 2012

Delaware district court upholds Pfizer's patents for LYRICA to treat pain and seizures

Pfizer Inc. announced today that the United States District Court for the District of Delaware upheld its composition of matter patent and pain and seizure use patents covering LYRICA (pregabalin) capsules CV. With this decision, Pfizer will exclusively provide pregabalin as LYRICA to patients through December 30, 2018 in the U.S., pending generic company appeal and further litigation.

20 Jul 2012

Quick-Med Technologies grants Derma Sciences global license to NIMBUS antimicrobial technology

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, and Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announce the signing of an agreement whereby Quick-Med Technologies has granted Derma Sciences an exclusive global license to intellectual property related to the novel NIMBUS antimicrobial technology, which is available in BIOGUARD dressings.

13 Jul 2012

U.K. High Court rules in favor of Teva in COPAXONE patent litigation

Teva Pharmaceutical Industries Ltd. announced that the United Kingdom High Court of Justice issued a decision in favor of Teva in a patent litigation proceeding against Generics (UK) Limited, a subsidiary of Mylan Laboratories Inc., on July 11, 2012.

12 Jul 2012

ImmunoCellular receives Japanese patent allowance for brain cancer technology

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of a Japanese patent relating to a technology for the treatment of brain cancer for which the Company holds an exclusive, worldwide license.

10 Jul 2012

AtheroNova receives U.S. patent allowance for 'Dissolution of Arterial Plaque'

AtheroNova Inc., a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced that it has received a Notice of Allowance for its patent application for Dissolution of Arterial Plaque.

10 Jul 2012

KannaLife enters exclusive license with NIH-OTT for patent regarding cannabinoids

KannaLife Sciences, Inc. Signs Exclusive License Agreement With National Institutes of Health – Office of Technology Transfer for the Commercialization of U.S. Patent 6,630,507, "Cannabinoids as Antioxidants and Neuroprotectants".

9 Jul 2012

Treatment of Schizophrenia receives notice of intention to grant a European patent

BioLineRx (NASDAQ:BLRX)(TASE:BLRX), a biopharmaceutical development company, announced today that it has received from the European Patent Office a notice of intention to grant a European patent claiming the salt of BL-1020, a first-in-class orally available treatment for schizophrenia.

9 Jul 2012

UPM researchers develop a functional biscuit for celiac patients

Researchers at the Universidad Politécnica de Madrid (UPM) have patented a biscuit which is made from teff flour, suitable for celiac patients, and, thanks to its nutritional properties, it is ideal for sportsmen, diabetics and people with anemia.

4 Jul 2012

USPTO issues notice of allowance to Avanir for NUEDEXTA

Avanir Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed a new patent that covers Avanir's product NUEDEXTA, further expanding the intellectual property portfolio for the company's lead commercial asset.

2 Jul 2012

CytRx granted European patent for tumor-targeting linker platform technology

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that the European Patent Office (EPO) has issued a patent covering the Company's tumor-targeting linker platform technology and pharmaceutical compositions.

2 Jul 2012

Humanetics receives U.S. patent for NIC5-15 to treat Alzheimer's

The US Patent and Trademark Office has issued a patent supporting a long-term, multi-year research and development collaboration between Mount Sinai School of Medicine (MSSM) and Humanetics Corporation to develop and commercialize a safe and effective means to prevent or slow the progression of Alzheimer's disease. Humanetics is the exclusive licensee for this patent.

28 Jun 2012

Nevro receives two key U.S. patents for Senza High-Frequency Spinal Cord Stimulation System

Nevro Corp., a medical device company focused on improving pain relief among patients suffering from debilitating chronic pain, announced today the issuance of two key patents related to the company's Senza High-Frequency Spinal Cord Stimulation System.

28 Jun 2012

Pfizer, Wyeth and PF Prism file suit against Watson over generic Pristiq

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Desvenlafaxine Succinate Extended-release Tablets, 50 mg and 100 mg.

26 Jun 2012

Thomson Reuters unveils new regulatory intelligence solution at DIA 2012

The Intellectual Property & Science division of Thomson Reuters unveiled Cortellis for Regulatory Intelligence™ at the DIA 2012 Annual Meeting in Philadelphia today. This new offering is the next generation of Thomson Reuters IDRAC™, the company's best-in-class regulatory intelligence tool that provides pharmaceutical professionals with reliable and accurate global regulatory information to gain competitive advantage and minimize regulatory risks.

25 Jun 2012

U.S. District Court rules in favor of Teva in COPAXONE patent infringement case

Teva Pharmaceutical Industries Ltd. announced today the U.S. District Court for the Southern District of New York has found in favor of Teva in the Company's patent infringement lawsuit against Momenta Pharmaceuticals, Inc./Sandoz Inc. and Mylan Laboratories Inc./Natco Pharmaceuticals regarding Teva's relapsing-remitting multiple sclerosis (RRMS) product, COPAXONE.

23 Jun 2012

DSM XD high cell density process technology granted patents in several countries

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM N.V., announced today that several countries have granted patents or have given statements of patent allowance to its proprietary XD® high cell density process technology.

19 Jun 2012

New patent filed for VAC-3S, an immunotherapy for treating HIV infections

InnaVirVax, a biopharmaceutical company specialized in the research and development of therapeutic and diagnostic innovations focused on immune dysregulation, announced today that a new European patent application has been filed on VAC-3S, a “first-in-class” immunotherapy for the treatment of HIV infections.